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Background
This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct 
inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in 
patients undergoing total hip arthroplasty.
Methods
In this randomized, double-blind study, we assigned 4541 patients to receive either 
10 mg of oral rivaroxaban once daily, beginning after surgery, or 40 mg of enoxaparin 
subcutaneously once daily, beginning the evening before surgery, plus a placebo tab-
let or injection. The primary efficacy outcome was the composite of deep-vein throm-
bosis (either symptomatic or detected by bilateral venography if the patient was 
asymptomatic), nonfatal pulmonary embolism, or death from any cause at 36 days 
(range, 30 to 42). The main secondary efficacy outcome was major venous thrombo-
embolism (proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death 
from venous thromboembolism). The primary safety outcome was major bleeding.
Results
A total of 3153 patients were included in the superiority analysis (after 1388 exclu-
sions), and 4433 were included in the safety analysis (after 108 exclusions). The pri-
mary efficacy outcome occurred in 18 of 1595 patients (1.1%) in the rivaroxaban group 
and in 58 of 1558 patients (3.7%) in the enoxaparin group (absolute risk reduction, 
2.6%; 95% confidence interval [CI], 1.5 to 3.7; P<0.001). Major venous thromboembo-
lism occurred in 4 of 1686 patients (0.2%) in the rivaroxaban group and in 33 of 1678 
patients (2.0%) in the enoxaparin group (absolute risk reduction, 1.7%; 95% CI, 1.0 to 
2.5; P<0.001). Major bleeding occurred in 6 of 2209 patients (0.3%) in the rivaroxa-
ban group and in 2 of 2224 patients (0.1%) in the enoxaparin group (P = 0.18).
Conclusions
A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for ex-
tended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxa-
parin in patients undergoing elective total hip arthroplasty. The two drugs had simi-
lar safety profiles. (ClinicalTrials.gov number, NCT00329628.)
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Prophylactic anticoagulant thera-py is standard practice after total hip or knee arthroplasty, with a minimum recommended 
duration of 10 days.1 After total hip arthroplasty, 
extended prophylaxis for 5 weeks after surgery re-
duces the incidence of symptomatic and asymp-
tomatic venous thromboembolism more effective-
ly than does short-term prophylaxis.2 New deep-vein 
thromboses have been shown to form after the dis-
continuation of short-term prophylaxis.3 Several 
meta-analyses suggest that extended thrombopro-
phylaxis after total hip arthroplasty leads to a re-
duction in symptomatic venous thromboembolic 
events, without increasing the risk of major bleed-
ing.4-6 These findings led to a grade 1A recommen-
dation for extended thromboprophylaxis after total 
hip arthroplasty in the guidelines of the American 
College of Chest Physicians.1
The current options for extended thrombopro-
phylaxis are limited. Low-molecular-weight hep-
arin preparations reduce thromboembolic events 
but need to be administered subcutaneously, and 
their cost-effectiveness has been shown only if 
patients or caregivers can be taught to inject the 
medication at home.7,8 Vitamin K antagonists, 
such as warfarin, have unpredictable pharmaco-
logic effects and numerous food and drug interac-
tions, require frequent monitoring, and are there-
fore difficult to manage.9 Furthermore, there is 
evidence to suggest that the incidence of major 
bleeding is greater with vitamin K antagonists 
than with low-molecular-weight heparin prepara-
tions given after total hip arthroplasty.10
Rivaroxaban is an oral direct inhibitor of fac-
tor Xa. The oral bioavailability of rivaroxaban is 
approximately 80%, and peak plasma concentra-
tions are achieved in 2.5 to 4 hours.11,12 Recent 
dose-finding studies in patients undergoing ma-
jor orthopedic surgery showed a close correlation 
between the pharmacokinetic and pharmacody-
namic effects of rivaroxaban and suggested that 
a 10-mg dose of rivaroxaban once daily was suit-
able for investigation in phase 3 trials.13-17
Our study, called Regulation of Coagulation in 
Orthopedic Surgery to Prevent Deep Venous Throm-
bosis and Pulmonary Embolism 1 (RECORD1), 
was a randomized, multinational, double-blind 
trial conducted to assess the efficacy and safety 
of a postoperative 10-mg oral dose of rivaroxaban 
given once daily as compared with a 40-mg sub-
cutaneous dose of enoxaparin (a low-molecular-
weight heparin), with the first dose given the 
evening before surgery and subsequent doses given 
once daily, for extended thromboprophylaxis after 
total hip arthroplasty.
Me thods
Patients
Men and women of at least 18 years of age who 
were scheduled to undergo elective total hip arthro-
plasty were eligible for inclusion. Patients were in-
eligible if they were scheduled to undergo staged, 
bilateral hip arthroplasty, were pregnant or breast-
feeding, had active bleeding or a high risk of bleed-
ing, or had a contraindication for prophylaxis with 
enoxaparin or a condition that might require an 
adjusted dose of enoxaparin. Other ineligibility cri-
teria were conditions preventing bilateral venog-
raphy, substantial liver disease, severe renal im-
pairment (creatinine clearance, <30 ml per minute), 
concomitant use of protease inhibitors for the 
treatment of human immunodeficiency virus in-
fection, planned intermittent pneumatic compres-
sion, or a requirement for anticoagulant therapy 
that could not be stopped.
Study Design and Drugs
Before surgery, patients were randomly assigned to 
a study group with the use of permuted blocks 
and stratification according to center by means of 
a central telephone system with a computer-gener-
ated randomization list. In a double-blind fashion, 
patients were assigned to receive either once-daily 
oral rivaroxaban in 10-mg tablets (Xarelto, Bayer 
HealthCare) or 40 mg of enoxaparin sodium ad-
ministered by subcutaneous injection (Clexane/
Lovenox, Sanofi-Aventis). Rivaroxaban was started 
6 to 8 hours after wound closure. Enoxaparin was 
initiated 12 hours before surgery and restarted 6 to 
8 hours after wound closure. Thereafter, study 
drugs were administered every 24 hours (range, 
22 to 26) in the evening through day 35 (range, 
31 to 39) after surgery (with the day of surgery 
defined as day 1). Patients also received placebo 
tablets or injections.
Patients underwent mandatory bilateral venog-
raphy the day after the last dose of the study drug, 
at 36 days (range, 30 to 42). No further study 
medication was given after venography, although 
further thromboprophylaxis was continued at 
the investigator’s discretion. Patients had a fol-
low-up visit 30 to 35 days after the last dose of 
the study drug.
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The trial was performed in accordance with 
the provisions of the Declaration of Helsinki and 
local regulations. The protocol was approved by 
the institutional review board at each center, and 
written informed consent was obtained from all 
patients before randomization.
The study was designed and supervised by a 
steering committee. The data were collected and 
analyzed by the sponsors of the study, Bayer 
HealthCare and Johnson & Johnson. All authors 
contributed to the writing of the manuscript, 
had full access to all the data and analyses, and 
vouch for the accuracy and completeness of the 
data reported.
Outcome Measures
All outcomes were assessed by central independent 
adjudication committees whose members were un-
aware of the patients’ study-group assignments. 
The primary efficacy outcome was the composite 
of any deep-vein thrombosis, nonfatal pulmonary 
embolism, or death from any cause up to 36 days 
(range, 30 to 42). The main secondary efficacy out-
come was major venous thromboembolism, which 
was defined as the composite of proximal deep-
vein thrombosis, nonfatal pulmonary embolism, 
or death from venous thromboembolism. Other 
efficacy outcomes included the incidence of deep-
vein thrombosis (any thrombosis, including both 
proximal and distal), the incidence of symptom-
atic venous thromboembolism during treatment 
and follow-up (30 to 35 days after the last dose of 
a study drug), and death during the follow-up 
period.
Deep-vein thrombosis was assessed at 36 days 
(range, 30 to 42) or earlier if the patient was symp-
tomatic, by means of systematic ascending, bilat-
eral venography with the use of the Rabinov and 
Paulin technique.18 In cases of suspected pulmo-
nary embolism, spiral computed tomography, per-
fusion–ventilation lung scintigraphy, or pulmo-
nary angiography was performed, and the films 
or images were sent to the central adjudication 
committee. Autopsies were requested in the event 
of a patient’s death.
The main safety outcome was the incidence of 
major bleeding beginning after the first dose of 
the study drug and up to 2 days after the last dose 
of the study drug (on-treatment period). Major 
bleeding was defined as bleeding that was fatal, 
occurred in a critical organ (e.g., retroperitoneal, 
intracranial, intraocular, and intraspinal bleeding), 
or required reoperation or extrasurgical-site bleed-
ing that was clinically overt and was associated 
with a fall in the hemoglobin level of at least 2 g 
per deciliter or that required transfusion of 2 or 
more units of whole blood or packed cells. Other 
safety outcomes included any on-treatment bleed-
ing, any on-treatment nonmajor bleeding, hem-
orrhagic wound complications (a composite of 
excessive wound hematoma and reported surgi-
cal-site bleeding), any bleeding that started after 
the first oral dose of rivaroxaban or placebo and 
ended up to 2 days after the last dose was admin-
istered, adverse events, and death.
During the study and at follow-up, laboratory 
variables, including liver enzymes, and cardiovas-
cular events were monitored. Cardiovascular events 
occurring up to 1 calendar day after the cessation 
of the study drug were classified as on-treatment 
events.
Statistical Analysis
The aim of the trial was first to test the null hy-
pothesis that the efficacy of rivaroxaban was infe-
rior to that of enoxaparin in the per-protocol pop-
ulation. If noninferiority was shown, a second 
analysis would determine whether the efficacy of 
rivaroxaban was superior to that of enoxaparin in 
the modified intention-to-treat population.
The modified intention-to-treat analysis in-
cluded patients who had undergone planned sur-
gery, had taken a study drug, and had undergone 
an adequate assessment for thromboembolism. 
These patients were included in the per-protocol 
analysis, provided they had no major deviation 
from the protocol (for details, see Table 1). The 
safety analysis included patients who had received 
at least one dose of a study drug. Patients were 
included in the assessment for major venous 
thromboembolism if the proximal veins could be 
evaluated on venography, regardless of whether 
the distal veins could be evaluated. 
The primary efficacy analysis was conducted 
for noninferiority in the per-protocol population 
and for superiority in the modified intention-to-
treat population. The difference between the inci-
dence rates in the rivaroxaban group and the 
enoxaparin group was estimated by stratification 
according to country, with the use of Mantel–
Haenszel weighting with a corresponding asymp-
totic two-sided 95% confidence interval. Testing 
for noninferiority and testing for superiority were 
both based on the 95% confidence interval. The 
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threshold for the noninferiority test was an abso-
lute margin of 3.5% for the primary efficacy out-
come and an absolute margin of 1.5% for major 
venous thromboembolism.
The sample-size calculation was based on an 
assumed rate of 8% for the primary efficacy out-
come with both study drugs and a noninferior-
ity threshold of 3.5%. If these assumptions were 
correct, 1562 patients per study group would be 
sufficient to show noninferiority with a power of 
95% and a one-sided type I error rate of 2.5%. It 
was assumed that 25% of patients would not have 
valid venograms, resulting in a target sample size 
of 4200 patients.
The analysis of the difference in the incidence 
of major bleeding between the study groups was 
performed in the same manner as that of effica-
cy; other safety outcomes were analyzed with the 
use of appropriate descriptive methods. For sex 
and other categorical variables, the two study 
groups were compared with the use of a Cochran–
Mantel–Haenszel test, adjusted for country. For 
continuous variables, the groups were compared 
by analysis of variance. All reported P values are 
two-sided, with a type I error rate of 5%. No in-
terim analyses were planned.
R esult s
Study Populations
Between February 2006 and March 2007, a total 
of 4591 patients were enrolled in 27 countries 
worldwide (Fig. 1). A total of 3029 patients were 
included in the per-protocol population, and 3153 
were included in the modified intention-to-treat 
population. The reasons for exclusion from the 
various analyses were similar between the two 
groups (Table 1). Demographic and surgical char-
acteristics were also similar between the two 
groups (Table 2). The mean duration of prophylaxis 
was 33.4 days in the rivaroxaban group and 33.7 
days in the enoxaparin group (safety population).
Efficacy Outcomes
In the per-protocol population, the primary effi-
cacy outcome occurred in 13 of 1537 patients (0.8%) 
in the rivaroxaban group and in 50 of 1492 pa-
tients (3.4%) in the enoxaparin group (weighted 
risk reduction in the rivaroxaban group, 2.5 per-
centage points; 95% confidence interval [CI], 1.5 to 
3.6). This analysis showed the noninferiority of ri-
varoxaban, as compared with enoxaparin. In the 
modified intention-to-treat population, the primary 
efficacy outcome occurred in 18 of 1595 patients 
(1.1%) in the rivaroxaban group and in 58 of 1558 
patients (3.7%) in the enoxaparin group (weighted 
risk reduction, 2.6 percentage points; 95% CI, 1.5 to 
3.7; P<0.001; relative risk reduction, 70%; 95% CI, 
49 to 82; P<0.001) (Table 3). This analysis showed 
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Figure 1. Enrollment and Outcomes.
Patients were included in the analysis of major venous thromboembolism 
(VTE) if proximal veins could be evaluated on venography, regardless of 
whether distal veins could be evaluated. Thus, patients in the modified 
 intention-to-treat (ITT) analysis of primary efficacy are not a subgroup of 
those in the per-protocol analysis of major VTE. 
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the superiority of rivaroxaban, as compared with 
enoxaparin.
In the per-protocol population, major venous 
thromboembolism occurred in 2 of 1622 patients 
(0.1%) in the rivaroxaban group and in 29 of 1604 
patients (1.8%) in the enoxaparin group (weighted 
risk reduction in the rivaroxaban group, 1.7 per-
centage points; 95% CI, 1.0 to 2.4). This analysis 
showed the noninferiority of rivaroxaban, as com-
pared with enoxaparin. In the modified intention-
to-treat population, major venous thromboembo-
lism occurred in 4 of 1686 patients (0.2%) in the 
rivaroxaban group and in 33 of 1678 patients 
(2.0%) in the enoxaparin group (weighted risk re-
duction, 1.7 percentage points; 95% CI, 1.0 to 2.5; 
P<0.001; relative risk reduction, 88%; 95% CI, 66 
to 96; P<0.001) (Table 3). This analysis showed 
the superiority of rivaroxaban, as compared with 
enoxaparin.
The observed rates of symptomatic venous 
thromboembolism among patients undergoing 
surgery who were included in the safety analysis 
were similar in the rivaroxaban group and the 
enoxaparin group (0.3% and 0.5%, respectively) 
(Table 3). During the treatment period, there were 
four deaths in each group in the safety population 
(0.2%). On the basis of adjudication, in the riva-
roxaban group, two deaths were possibly related 
Table 1. Criteria for the Exclusion of Patients from Analyses. 
Variable Rivaroxaban Enoxaparin
no. (%)
Underwent randomization 2266 2275
Did not receive a study drug 57 (2.5) 51 (2.2)
Included in safety analysis 2209 (97.5) 2224 (97.8)
Did not undergo planned surgery 17 (0.8) 21 (0.9)
No surgery 16 (0.7) 18 (0.8)
Not prespecified surgery 1 (<0.1) 3 (0.1)
Received wrong study drug 1 (<0.1) 2 (0.1)
Had inadequate assessment of thromboembolism 588 (25.9) 635 (27.9)
Venography not performed 319 (14.1) 322 (14.2)
Unilateral venography performed 105 (4.6) 105 (4.6) 
Venographic findings indeterminate or could not be evaluated 121 (5.3) 164 (7.2) 
Venography not performed by day 36±6 43 (1.9) 44 (1.9) 
Inadequate evaluation of efficacy (source data not verified) 8 (0.4) 8 (0.4)
Included in modified intention-to-treat analysis of primary efficacy 1595 (70.4) 1558 (68.5)
Received first postoperative dose of study drug >24 hr after surgery 16 (0.7) 16 (0.7)
Assessment of venous thromboembolism outside time window* 20 (0.9) 26 (1.1)
Compliance <80% 16 (0.7) 16 (0.7)
Received wrong study drug 1 (<0.1) 1 (<0.1)
Received a prohibited anticoagulant 5 (0.2) 7 (0.3)
Included in per-protocol analysis of primary efficacy 1537 (67.8) 1492 (65.6)
Included in analysis of symptomatic venous thromboembolism (safety  
population of patients who underwent surgery)
2193 (96.8) 2206 (97.0)
Included in modified intention-to-treat analysis of major venous thrombo-
embolism†
1686 (74.4) 1678 (73.8)
Included in per-protocol analysis of major venous thromboembolism† 1622 (71.6) 1604 (70.5)
* Assessment of venous thromboembolism was considered to be outside the time window if it was performed more than 
36 hours after the last dose of a study drug for a positive result or more than 72 hours after the last dose of a study 
drug for a negative result. 
† Patients were included in the analysis of major venous thromboembolism if proximal veins could be evaluated on ve-
nography, regardless of whether distal veins could be evaluated. 
The New England Journal of Medicine 
Downloaded from nejm.org at Universita' degli Studi dell'Insubria on November 15, 2016. For personal use only. No other uses without permission. 
 Copyright © 2008 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
n engl j med 358;26 www.nejm.org june 26, 20082770
to venous thromboembolism, and two deaths were 
unrelated to venous thromboembolism; in the 
enoxaparin group, one death was related to ve-
nous thromboembolism, and three deaths were 
unrelated to venous thromboembolism. During 
the follow-up period, in the rivaroxaban group, 
one patient had symptomatic proximal deep-vein 
thrombosis and one patient died from causes un-
related to venous thromboembolism; in the enoxa-
parin group, three patients had symptomatic prox-
imal deep-vein thrombosis and one patient had 
distal deep-vein thrombosis.
safety outcomes
Major bleeding occurred in 6 of 2209 patients 
(0.3%) in the rivaroxaban group and in 2 of 2224 
patients (0.1%) patients in the enoxaparin group 
(unweighted absolute increase in risk in the riva-
roxaban group, 0.2%; 95% CI, −0.1 to 0.5) (Tables 
4 and 5). In the rivaroxaban group, there was one 
fatal bleeding event, which occurred before the 
administration of the first dose of rivaroxaban, and 
one intraocular bleeding event, which resolved 
without discontinuation of rivaroxaban (Table 5). 
The combined incidence of major and clinically 
relevant nonmajor bleeding events was 3.2% (70 
of 2209 patients) in the rivaroxaban group and 
2.5% (56 of 2224 patients) in the enoxaparin group 
(weighted absolute increase in risk, 0.6%; 95% CI, 
–0.4 to 1.6). The incidence of hemorrhagic wound 
complications was similar in the two groups, oc-
curring in 1.5% of patients in the rivaroxaban 
group and in 1.7% of patients in the enoxaparin 
group. The number of patients receiving blood 
transfusions and the median amount of blood in 
the postoperative drain were similar in the two 
groups, as was the incidence of all bleeding events 
(Table 4).
Other Observations
Rivaroxaban and enoxaparin were associated with 
a similar number of adverse events (Table 4; and 
Table 1 in the Supplementary Appendix, available 
with the full text of this article at www.nejm.org). 
An on-treatment elevation in the plasma alanine 
aminotransferase level (i.e., a level of more than 
three times the upper limit of the normal range) 
occurred in 43 of 2128 patients (2.0%) in the riv-
aroxaban group, with all cases resolving by the 
end of the follow-up period, and in 57 of 2129 pa-
tients (2.7%) in the enoxaparin group, with all 
cases resolving by the end of the follow-up period 
(with no follow-up data available for 1 patient who 
withdrew from the study). One patient in each 
group had an elevated alanine aminotransferase 
level and a concomitant bilirubin level of more than 
twice the upper limit of the normal range. The 
Table 2. Demographic and Clinical Characteristics of the Patients (Safety 
Population).
Characteristic
Rivaroxaban 
(N = 2209)
Enoxaparin 
(N = 2224)
Female sex — no. (%) 1220 (55.2) 1242 (55.8)
Age — yr
Mean 63.1 63.3
Range 18–91 18–93
Weight — kg
Mean 78.1 78.3
Range 37–159 40–132
Body-mass index*
Mean 27.8 27.9
Range 16.2–53.4 15.2–50.2
Race or ethnic group — no. (%)†
White 2041 (92.4) 2049 (92.1)
Hispanic 22 (1.0) 31 (1.4)
Black 20 (0.9) 19 (0.9)
Asian 5 (0.2) 2 (0.1)
Other or missing data 121 (5.5) 123 (5.5)
History of venous thromboembolism — 
no. (%)
47 (2.1) 55 (2.5)
Previous orthopedic surgery — no. (%) 490 (22.2) 500 (22.5)
Type of surgery — no. (%)
Primary 2127 (96.3) 2118 (95.2)
Revision 66 (3.0) 86 (3.9)
No surgery or missing data 16 (0.7) 20 (0.9)
Use of cement — no. (%) 857 (38.8) 869 (39.1)
Type of anesthesia — no. (%)
General only 661 (29.9) 648 (29.1)
General and regional 223 (10.1) 228 (10.3)
Regional only 1308 (59.2) 1330 (59.8)
Missing data 17 (0.8) 18 (0.8)
Duration of surgery — min
Mean 90.6 91.3
Range 27–480 25–345
* The body-mass index is the weight in kilograms divided by the square of the 
height in meters.
† Race or ethnic group was assessed by investigators according to disclosure 
requirements in each country.
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liver enzyme levels resolved with continued admin-
istration of rivaroxaban and with the discontinua-
tion of enoxaparin, according to the prespecified 
criteria. During the entire study period, 13 car-
diovascular events occurred in 11 patients in the 
rivaroxaban group, and 10 events occurred in 10 
patients in the enoxaparin group. Of these cardio-
vascular events, on-treatment events occurred in 
five patients in the rivaroxaban group and in nine 
patients in the enoxaparin group; during follow-
up, eight events occurred in seven patients in the 
rivaroxaban group, and one patient had an event 
in the enoxaparin group (Table 4).
Discussion
This trial showed that oral, once-daily rivaroxaban 
has potential for extended thromboprophylaxis af-
ter total hip arthroplasty. Rivaroxaban was signifi-
cantly more effective than enoxaparin for the pre-
vention of venous thromboembolic events. Among 
patients receiving rivaroxaban, as compared with 
those receiving enoxaparin, there was an absolute 
risk reduction of 2.6% (relative risk reduction, 70%) 
for the primary efficacy outcome of deep-vein 
thrombosis, pulmonary embolism, or death from 
any cause and an absolute risk reduction of 1.7% 
(relative risk reduction, 88%) for major venous 
thromboembolism. 
The superior efficacy of rivaroxaban was not 
associated with any significant increases in the 
incidence of major bleeding or any other bleeding 
events. The number of major bleeding events in 
this study was lower than that reported in several 
other studies,19-21 which may be due, in part, to 
the difference in definitions of bleeding that were 
used in the various studies. Almost half the pa-
tients who undergo this type of surgical proce-
dure require a transfusion of 2 or more units of 
blood.15,16,22-24 In our study, the inclusion of a 
secondary bleeding outcome, hemorrhagic wound 
complication (which encompassed surgical-site 
Table 3. Incidence of Efficacy Events (Modified Intention-to-Treat Population).
Outcome Rivaroxaban Enoxaparin
Absolute Risk  
Reduction* P Value†
no. with events/ 
total no. % (95% CI)
no. with events/
total no. % (95% CI) % (95% CI)
Primary efficacy outcome‡ 18/1595 1.1 (0.7 to 1.8) 58/1558 3.7 (2.8 to 4.8) –2.6 (–3.7 to –1.5) <0.001
Major venous thromboembolism§ 4/1686 0.2 (0.1 to 0.6) 33/1678 2.0 (1.4 to 2.8) –1.7 (–2.5 to –1.0) <0.001
Death during on-treatment period 4/1595 0.3 (0.1 to 0.6) 4/1558 0.3 (0.1 to 0.7) 0.0 (–0.4 to 0.4) 1.00
Nonfatal pulmonary embolism 4/1595 0.3 (0.1 to 0.6) 1/1558 0.1 (<0.1 to 0.4) 0.2 (–0.1 to 0.6) 0.37
Deep-vein thrombosis 12/1595 0.8 (0.4 to 1.3) 53/1558 3.4 (2.6 to 4.4) –2.7 (–3.7 to –1.7) <0.001
Proximal 1/1595 0.1 (<0.1 to 0.4) 31/1558 2.0 (1.4 to 2.8) –1.9 (–2.7 to –1.2) <0.001
Distal only 11/1595 0.7 (0.3 to 1.2) 22/1558 1.4 (0.9 to 2.1) –0.7 (–1.5 to 0.0) 0.04
Symptomatic venous thromboembo-
lism¶
During treatment 6/2193 0.3 (0.1 to 0.6) 11/2206 0.5 (0.3 to 0.9) –0.2 (–0.6 to 0.1) 0.22
During follow-up 1/2193 <0.1 (<0.1 to 0.3) 4/2206 0.2 (0.1 to 0.5) –0.1 (–0.4 to 0.1) 0.37
Death during follow-up 1/1595 0.1 (<0.1 to 0.4) 0/1558 0.0 (0.0 to 0.2) 0.1 (–0.2 to 0.4) 1.00
* The absolute risk reduction, calculated with the use of a weighted Mantel–Haenszel test, is for patients receiving rivaroxaban, as compared 
with those receiving enoxaparin. For outcomes that occurred infrequently (i.e., fewer than 10 events in total, including death, pulmonary 
embolism, and symptomatic venous thromboembolism during follow-up), unweighted risk reductions and exact confidence intervals are 
given.
† Values were calculated on the basis of the Mantel–Haenszel weighted estimator. For outcomes that occurred infrequently (i.e., fewer than 
10 events in total, including death, pulmonary embolism, and symptomatic venous thromboembolism during the follow-up period), the list-
ed P values were calculated with the use of Fisher’s exact test.
‡ The primary efficacy outcome was a composite of any deep-vein thrombosis, nonfatal pulmonary embolism, or death from any cause. 
§ Major venous thromboembolism was a composite of proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death from venous 
thromboembolism.
¶ Symptomatic venous thromboembolism included any symptomatic deep-vein thrombosis (proximal or distal) and nonfatal or fatal symp-
tomatic pulmonary embolism in patients in the safety population who had undergone surgery.
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Table 4. Adverse Events (Safety Population).*
Event
Rivaroxaban 
(N = 2209)
Enoxaparin 
(N = 2224) P Value
Any on-treatment bleeding  — no. (%)† 133 (6.0) 131 (5.9) 0.94
Major bleeding 
No. of patients (%) 6 (0.3) 2 (0.1) 0.18
95% CI — % 0.1–0.6 <0.1–0.3
Fatal bleeding — no. (%) 1 (<0.1)‡ 0 
Bleeding into a critical organ — no. (%) 1 (<0.1) 0 
Bleeding leading to reoperation — no. (%) 2 (0.1) 1 (<0.1)
Clinically overt extrasurgical-site bleeding — no. (%)
Leading to a fall in hemoglobin 2 (0.1) 1 (<0.1)
Leading to transfusion of ≥2 units of blood 2 (0.1) 1 (<0.1)
Nonmajor bleeding — no. (%) 128 (5.8) 129 (5.8)
Clinically relevant 65 (2.9) 54 (2.4)
Hemorrhagic wound complication (composite of exces-
sive wound hematoma and reported surgical-
site bleeding) 
34 (1.5) 38 (1.7)
Other nonmajor bleeding 71 (3.2) 77 (3.5)
Postoperative wound infection — no. (%)§ 8 (0.4) 8 (0.4)
Any bleeding beginning after first rivaroxaban or placebo 
tablet  — no./total no. (%)¶
119/2183 (5.5) 109/2198 (5.0)
Patients receiving blood transfusions — no. (%) 1210 (54.8) 1249 (56.2)
Volume of blood transfusion in patients who had transfu-
sions — ml
Median 568 585
Range 50–3577 20–6561
Patients with postoperative drain — no. (%) 1833 (83.0) 1849 (83.1)
Volume in drain in patients for whom data were available 
— ml
Median 540 530
Range 6–5180 2–3490
Any on-treatment adverse event — no. (%) 1413 (64.0) 1439 (64.7)
Drug-related adverse event — no. (%) 270 (12.2) 265 (11.9)
Cardiovascular event — no. (%)
During on-treatment period‖ 5 (0.2) 9 (0.4)
Death 1 (<0.1) 0
Ischemic stroke 1 (<0.1) 3 (0.1)
Myocardial infarction 3 (0.1) 6 (0.3)
During follow-up** 7 (0.3) 1 (<0.1)
Death 2 (<0.1)†† 1 (<0.1)
Ischemic stroke 2 (<0.1)‡‡ 0
Myocardial infarction 4 (0.2)‡‡ 0
* Patients could have more than one event, and an event could fall into more than one category. 
† Adjudicated on-treatment bleeding events included those beginning after the initiation of the study drug and up to 
2 days after the last dose of the study drug.
‡ The event occurred before the administration of the first dose of rivaroxaban.
§ The definition for this event is listed in the Medical Dictionary for Regulatory Activities.
¶ Adjudicated on-treatment bleeding events beginning after the first rivaroxaban or placebo tablet were those that oc-
curred up to 2 days after the last dose of the study drug. The denominator is the number of patients in the safety 
population who received at least one tablet of rivaroxaban or placebo.
‖ On-treatment events occurred up to 1 calendar day after the last dose of the study drug.
** Events during follow-up occurred more than 1 calendar day after the last dose of the study drug.
†† One patient also had an on-treatment cardiovascular event.
‡‡ One patient had both an ischemic stroke and a myocardial infarction during follow-up. 
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bleeding and excessive wound hematoma), allowed 
such events to be reported, and there was no sig-
nificant difference in bleeding outcomes between 
the two groups. There were similar incidences of 
elevated liver enzyme levels in the two groups dur-
ing the 5-week on-treatment period.
As in most other phase 3 clinical trials of 
thromboprophylaxis in orthopedic patients, the 
patients who were included in the efficacy analy-
sis did not include those who did not undergo an 
adequate assessment (i.e., venography) for the 
presence or absence of deep-vein thrombosis.25,26 
In our study, 67% of the patients were included 
in the per-protocol population. Because the num-
ber of valid venograms was smaller than expect-
ed, the steering committee increased the recruit-
ment of patients beyond the planned 4200 patients 
to more than 4500 patients to maintain the sta-
tistical power of the trial.
Several sensitivity analyses were performed to 
ensure that missing data did not affect the power 
of the trial or bias the outcome. These analyses 
supported the main finding of the study that 
there was a significant reduction in the incidence 
of the primary outcome in patients receiving riv-
aroxaban, as compared with those receiving 
enoxaparin. When all adjudicated events — pos-
itive results on venography, symptomatic events, 
and deaths — and all venograms that were ad-
judicated to show no deep-vein thrombosis were 
considered (regardless of whether they occurred 
outside the predefined time windows), the weight-
ed absolute risk reduction for the primary outcome 
in the rivaroxaban group, as compared with the 
enoxaparin group, was 2.7% (95% CI, 1.6 to 3.8). 
Furthermore, in cases in which the assessment 
of the central adjudication committee was not 
clear and all available assessments by investiga-
Table 5. On-Treatment Major Bleeding Events (Safety Population).
Variable No. Site Timing Details
Rivaroxaban 
Major bleeding 6
Fatal bleeding 1 Surgical During surgery No rivaroxaban had been given
Bleeding into a critical organ 1 Intraocular Day of surgery Patient had Gaucher’s disease and a his-
tory of intraocular bleeding 
Bleeding leading to reoperation 2
First patient Surgical Day of surgery Reoperation was wound revision due to 
serosanguineous drainage
Second patient Surgical 17 Days after surgery Reoperation for hematoma 
Clinically overt extrasurgical-site bleeding 
leading to a fall in hemoglobin 
and transfusion of ≥2 units of 
blood
2
First patient Gastrointestinal 2 Days after surgery “Coffee-ground” vomiting; patient had a 
history of peptic ulcer disease; rivarox-
aban was discontinued
Second patient Gastrointestinal 21 Days after surgery Gastrointestinal bleeding requiring trans-
fusion of 2 units of blood; endoscopy 
showed gastropathy consistent with 
the use of nonsteroidal antiinflamma-
tory drugs
Enoxaparin
Major bleeding 2
Bleeding leading to reoperation 1 Surgical Day of surgery Arterial bleeding; wound revision was per-
formed; enoxaparin was discontinued
Clinically overt extrasurgical-site 
bleeding leading to a fall in he-
moglobin and transfusion of 
≥2 units of blood
1 Gastrointestinal 13 Days after surgery Melena diagnosed as bleeding in the up-
per gastrointestinal tract; patient re-
covered within 1 day; enoxaparin was 
discontinued
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tors were included in addition to the above analy-
sis, the weighted absolute risk reduction was 3.0% 
(95% CI, 1.8 to 4.1) in the rivaroxaban group, as 
compared with the enoxaparin group. Thus, our 
study showed that extended thromboprophylaxis 
with 10 mg of rivaroxaban once daily for 5 weeks 
resulted in a very low incidence of thrombosis, with 
a safety profile similar to that of enoxaparin.
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